Absci teams up to help develop antibody drugs for cancer

mediaphotos

• Absci (NASDAQ:ABSI) said it signed a collaboration agreement with an undisclosed biotech company.
• Absci noted that the partner is a stealth-mode company, led by biotech industry executives, focused on developing antibody-drug-conjugates (ADCs) initially for cancer indications.
• The partner company has developed proprietary warhead linker chemistries that it will target to specified sites on subject antibodies by using Absci's Bionic Protein non-standard amino acid (nsAA) incorporation technology, according to Absci's July 7 press release.
• "We are pleased to be working with our partner to enable them to develop novel ADCs based on our Bionic Protein technology,” said Absci Founder and CEO Sean McClain.
• The collaboration calls for Absci to generate up to seven novel Bionic Antibodies using nsAAs.